Sputnik V Vaccine Latest News: RDIF, which manufactures Sputnik V Vaccine, has signed deals with pharmaceutical companies in India to produce crores of doses. This vaccine has been approved for emergency use in India.
Another vaccine of coronavirus has been approved in India. The Kovid-19 vaccine Sputnik V developed in Russia has been approved by the government panel. Phase 3 trial of this vaccine is going on in the country. Although this was the first vaccine to achieve regulatory approval in the world, other countries did not give it much importance due to a lack of sufficient trial data.
In India, two coronavirus vaccines – Covishield and Covaxin – have received approval in the first week of January 2021. Let us know how different Sputnik V is from Covishield or Covaxin.
How effective are these three vaccines of coronavirus?
ApkC of the Sputnik V vaccine has been found to be 91.6% in the interim results of the Phase 3 trial.
Bharat Biotech’s Covaxin achieved an Effec of 81% in Phase 3 clinical trials.
The serum institute of India’s Covishield had an affection of 62%. However affect reached 90% when given one and a half doses.
What is dosage pattern and method of storage?
Two doses of Covishield are given at intervals of 4-8 weeks. Sub-zero temperature (less than zero) is not required to store it.
Two doses of Covaxin are given at intervals of 4-6 weeks. It can also be stored at temperatures between 2-8 ° C.
According to the developers of Sputnik V, it can also be stored between 2-8 ° C temperature. This vaccine is also given in two doses.
What is the price and availability of the scene?
Both Covishield and Covaxin are being offered free of cost in government hospitals. 250 per dose is being charged for going to a private hospital. The government is giving Rs 150 per dose to Serum Institute and Bharat Biotech.
The price of Sputnik V in India is not yet clear. This vaccine abroad is less than $ 10 per dose. RDIF’s initial plan is to import it from Russia. In such a situation, the price may be higher.
Once production of this vaccine starts in India, the prices will be reduced considerably. Dr. Reddy Laboratories has signed a deal to make 10 crore doses. Apart from this, RDIF has also tied up to make 85 crore doses from Hetero Biopharma, Gland Pharma, Stellis Biopharma, Victory Biotech.
